Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer

Overview of attention for article published in Cancer Research, May 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 3,137 followers.

RT @santhoshak23220: Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Prev…

Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer @CCR_AACR @batraatulmd https://t.co/48q0uHQwhC

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.